CanaQuest Medical Corp.
Award-winning, Clinical Stage/Life-Sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The company is targeting anxiety, depression, and PTSD, including addiction. The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist with over 20 years of experience in the field of mental health and cannabinoids at Western University. Dr. Laviolette and his team of 13 scientists made two amazing discoveries that are Drug Candidates targeting neurological conditions: Drug Candidate for epilepsy, CQ-001, is supported by (cannabidiol “CBD” + IP formula) - molecules bond and synergistically attach to PPAR receptors allowing CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trials.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2008
- Employees:
- 1-10
- Turnover:
- less than $1,000,000 US
About Us
Novel Formulation Bases and Pre-clinical Trial Results for Rx Drug Candidates
CanaQuest Medical is a clinical-stage life sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors.
CanaQuest is collaborating with multiple Canadian universities including a Western University team led by Dr. Steven Laviolette, who has decades of research experience focused on novel pharmacotherapies to treat neurological conditions, such as anxiety, depression, schizophrenia, and Post Traumatic Stress Disorder “PTSD”, including addiction.
Dr. Laviolette’s team has made two amazing drug candidate discoveries, Rx CQ-001 (CBD molecules + formula) and Rx CQ-002 (THC molecules + formula), for treating mental ailments. Pre-clinical trials completed – setting the stage for pre-approved clinical trials.
To learn more about our value proposition and our pre-approved clinical trials, view our Corporate Presentation by clicking the thumbnail graphic further down.
2022 Global Excellence Awards
Best Medical Cannabis and Botanical Oils Product Development Company, 2022 – North America
Awarded by Global Health & Pharma, UK
Game Changing Formulations - IP Protected, International Patents Filed
- Drug candidate, CQ-001, supported by (cannabidiol “CBD” + IP formula) – molecules bond and synergistically attach to PPAR receptors allowing CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy.
CBD by itself did not do this in the pre-clinical trials.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience. Oct. 2020.
- Drug candidate, CQ-002, supported by (cannabinoid “THC” + IP formula) – is a safer alternative to all other THC products. Pre-clinical trials demonstrated reversal of depression-like and schizophrenia related symptoms, complete blockage of memory impairment, hyperactive activity, and gene vulnerability.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience Oct. 2020 & International Journal of Molecular Sciences July 2021.
The Company intends to incorporate Artificial Intelligence (AI) to help diagnose and evaluate mental health at the beginning and through the medication period. By including advanced machine learning algorithms, novel formulation methods, and well-established industry approaches, we are driving the evolution of the mental health industry to improve the lives of millions globally.
CanaQuest has research and clinical trial collaborations with multiple Canadian universities and Institutions and has identified the regulatory pathways for CQ-001 to obtain Rx Drug Identification Numbers (DINs) in the USA and Canada for Epilepsy rare neurological conditions, projected ∼ 3 years.
Western University
Pre-clinical trials completed for CQ-001 and CQ-002
Dr. Laviolette is a scientific veteran with 20 years of research experience in the field of mental health and cannabinoids and he oversees a dedicated team of 13 scientists, with a focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and Addiction.
University of Montreal
Q2 2022 – initiating pre-approved clinical trial (Phase II, randomized, triple-blind crossover feasibility study) for efficacy and dosage of our cannabinoid based formulated drug-candidates, CQ-001 and CQ-002, for the treatment of Cannabis Use Disorder “CUD”.
McMaster University
Q3 2022 – initiating clinical trial (Phase II, double-blind feasibility trial, 30 patients) to further refine efficacy and dosage of CQ-001 for humans.
Ontario Brain Institute
Q2 2022 – EpLink, the Epilepsy Research Program funded by the Ontario Brain Institute, is conducting a study using rodent models to establish dosing requirements for CQ-001. These results will set the stage for clinical trials to treat refractory epileptic syndromes (high efficacy, less dosage, reduced negative side effects).
Q4 2022 – study results will define dosage of CQ-001 for clinical trial (Phase II/III, double-blind trial, 60 patients) and will facilitate a submission to Health Canada and subsequently, the US-FDA for a new drug.
Hydrx Farms
Q3 2022 – our Contract Manufacturer, GMP and clinical trial compliance, is completing the SOPs for the Clinical Trial Application process required for the approved and funded clinical trial at the University of Montreal (Cannabis Use Disorder – efficacy, dosage, and safety, 24 patients), for evaluating CanaQuest’s CQ-001 and CQ-002 drug candidates.
Pre-approved and Pending Clinical Trials
The Company is primed to realize the infinite potential of targeted therapeutics within the endocannabinoid system and specific brain receptors to mediated signaling pathways.
CanaQuest has won Best Medical Cannabis and Botanical Oils Product Development Company, 2022 – North America………awarded by Global Health & Pharma, UK.
Focus Areas
- Anxiety
- Addiction
- Depression
- Schizophrenia
- PTSD
- Chronic Pain
Our Vision
Our vision is to be a global leader in the formulation and development of medicine derived from cannabinoids and other botanical-based molecules.
Business Strategy
Company Direction
CanaQuest is focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company intends to treat neurological conditions, such as anxiety, depression, schizophrenia, epilepsy, and Post Traumatic Stress Disorder “PTSD”, including addiction.
CanaQuest’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies.
Strategy
CanaQuest’s strategy is to:
- Continue developing scientific-backed proprietary formulations with its scientific partners, backed by pre-clinical trial results.
- Conduct clinical trials for drug candidates with universities and institutions (pre-approved & funded, and pending clinical trials)
- Partner with a global pharmaceutical organization.
CanaQuest has research and clinical trial collaborations with multiple Canadian universities, including a Western University team led by Dr. Steven Laviolette, a neuroscientist, who has decades of research and pre-clinical trial experience, focused on novel cannabinoid and botanical pharmacotherapies, addressing neurological conditions
The Company has brought together a wealth of management, commercialization, research & development, clinical trial, and regulatory expertise. As well, advanced manufacturing and pharmaceutical marketing/sales capabilities are in place.
CanaQuest is leveraging its multidisciplinary expertise by strengthening its Board of Directors and inviting Physicians, Psychiatrists, Healthcare Practitioners and regulatory professionals to join its Medical Advisory Board.
Advisor Shared Values and Expertise:- Shared passion to make a real difference in quality of life
- Scientific knowledge and expertise in cannabinoid-based medicine
- Currently or amenable to prescribing cannabinoids.
The Company is following the same regulatory pathway that GW Pharma took to obtain approvals for Epidiolex to treat Dravet & Lennox Gastaut Syndromes, rare neurological conditions under the umbrella of epilepsy.
Regulatory pathways are mapped out for RX CQ-001 to obtain Rx Drug Identification Numbers (DINs) in the USA and Canada for Epilepsy rare neurological conditions, with projected approvals in about 3 years.
Pre-clinical trials have been completed by Western University for Rx CQ-001 & Rx CQ-002.
Drug candidate, Rx CQ-001, supported by (CBD molecules + formula) – molecules bond and synergistically attach to PPAR receptor allowing Rx CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this.
Epidiolex Formula is 99% CBD – sesame as carrier oil (non-active)
Pre-Approved and Pending Clinical Trials are as Follows:
University of Montreal
Q2 2022 – initiating pre-approved clinical trial (Phase II, randomized, triple-blind crossover feasibility study) for efficacy and dosage of our cannabinoid based formulated drug-candidates, Rx CQ-001 and Rx CQ-002, for the treatment of Cannabis Use Disorder “CUD”. https://labo-jutras-aswad.ca/en/laboratory/
McMaster University
Ontario Brain Institute
Ontario Brain Institute
Q1 2022 – EpLink https://eplink.ca/, the Epilepsy Research Program funded by the Ontario Brain Institute, will conduct a study using rodent models to establish dosing requirements for Rx CQ-001. These results will set the stage for clinical trials to treat refractory epileptic syndromes (high efficacy, less dosage, reduced negative side effects).
Q4 2022 – study results will define dosage of Rx CQ-001 for clinical trial (Phase II/III, double-blind trial, 60 patients) and will facilitate a submission to Health Canada and subsequently, the US-FDA for a new drug.
Partners
The Company’s business model is to develop formulated drug candidates, backed by science, and pre-clinical & clinical trials for medicinal purposes. CanaQuest is looking to partner with a manufacturer that has global pharmaceutical production capabilities, expertise, including distribution networks. This model enables the Company to process and distribute anywhere in the world, subject to being compliant with the respective country’s regulations.
Working with Dr. Steve Laviolette, a professor and neuroscientist, at Western University, who has over 20 years of research experience in the field of mental health and cannabinoids and who oversees a team of 13 scientists, gives CanaQuest a tremendous competitive advantage. Successful pre-clinical trial results have set the stage for human trials in pursuit of pharmaceutical drugs. Clinical Trial opportunities are significant as several cannabinoid researchers, in the Canadian university sector, have fully funded grants awarded to undertake cannabinoid research including clinical trials.
The Company has identified the Rx regulatory pathway for a Pharma drug candidate, targeting neurological conditions – initiating Human Clinical Trials. It is following the FDA regulatory pathway developed by Jazz Pharmaceuticals (formerly GW Pharma) for the approval of Epidiolex.
Drug Candidate Formulations
CanaQuest is primed to realize the infinite potential of targeted therapeutics within the endocannabinoid system and specific brain receptors to mediated signaling pathways.
CQ-001, Drug Candidate – Epilepsy (CBD molecules + formula)
Clinical-trial stage
Supports anxiety, depression, schizophrenia, PTSD and addiction
CQ-002, Drug Candidate – Safer alternative (THC molecules + formula)
Clinical-trial stage
Supports mental health: safer alternative to THC by itself
CQ-003, Drug Candidate – Pain (CBD molecules + formula)
In development
To support inflammation & pain
CQ-004, Drug Candidate – Alzheimer’s (THC + CBD molecules + formula)
In development
To support mental health
Technology
The problem is that Mental Disorders are on the rise and there is limited science behind “medical” cannabinoid products.
- Global cost – mental disorders will cost the global economy $16 trillion by 20301
- Mental health ailments – 1 in 5 North Americans has some type of mental health condition2,3,4
- Limited science-backed cannabinoid natural plant solutions – to treat mental Illnesses (alternative to opioids)
- Cannabinoid medicine – physicians have a difficult time prescribing precise doses
- Neurological treatment limitations – cannabidiol (CBD) by itself does not effectively cross the blood-brain barrier
- Only one CBD pharmaceutical drug on the market – approved by the US-FDA – to treat epileptic neurological conditions – Epidiolex®, developed by former GW Pharma
CanaQuest has a solution.
Game Changing Formulations – IP protected, International Patents Filed
- Drug candidate, Rx CQ-001, supported by (CBD molecules + formula) – molecules bond and synergistically attach to PPAR receptor allowing Rx CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience. Oct. 2020.
- Drug candidate, Rx CQ-002, supported by (THC molecules + formula) – is a safer alternative to all other THC products. Pre-clinical trials demonstrated reversal of depression-like and schizophrenia related symptoms, complete blockage of memory impairment, hyperactive activity, and gene vulnerability.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience Oct. 2020 & International Journal of Molecular Sciences July 2021.
1) Psychiatric Times, November 2018
2) Open Minds, May 13, 2020
3) Mental Health Commission of Canada
4) National Alliance on Mental Illness (NAMI)
Strategy
- Continue developing scientific-backed proprietary formulations with its scientific partners, backed by pre-clinical trial results.
- Conduct clinical trials for drug candidates with universities and institutions (pre-approved & funded, and pending clinical trials)
- Partner with a global pharmaceutical organization.
- University of Montreal (Phase II)………pre-approved and funded
- McMaster University (Phase II)…………pre-approved and funded
- Ontario Brain Institute (Phase II/III)….clinical study funded & a pending clinical trial
Sustainability
Sustainability is a crucial consideration for all businesses, whether they realize it or not.
CanaQuest Medical Corp has made a concerted effort to create drug candidates that put the health of the world at its core.
By utilizing cannabinoid molecules and other botanical molecules, combined with university collaboration, we create drug candidates that will contribute to a healthier and happier planet.
Social Responsibility
CanaQuest Medical Corp is committed to upholding and respecting Canadian values and human rights in all of our business dealings. For us, this commitment means that we strive to govern ourselves according to a spirit of fairness and environmental awareness.
Environment
At its core, CanaQuest Medical Corp is an environmental company. By supplanting carbon-intensive alternatives to our products (such as high-protein meats, marine based Omega-3, and others), we are helping to turn the tide on climate change. As CanaQuest grows, we will continue to find ways to minimize our environmental impact.
Discrimination
As a global company, CanaQuest Medical Corp embraces diversity and respects differences in cultures, religions, and socio-economic statuses. We are aware of the damage that workplace discrimination can do to people and emerging economies. We are also aware that discrimination does not make business sense for us or our clients. For these reasons, CabaQuest views skill, qualifications, and experience as the basis of recruitment. In our dealings with other entities, we will not enter into contracts that contain any discriminatory workplace clauses, nor will we contemplate working with entities that have discriminatory policies.
Further, we commit ourselves to being aware of formal structures and informal cultural issues that can prevent employees from raising concerns and grievances, and will work to bypass these.
Human Rights
CanaQuest Medical Corp will not work with companies or individuals suspected of committing human rights abuses, or where we feel that our participation in a project may endanger human rights. Where we have concerns, we will review ongoing relationships and encourage clients to continue to observe human rights in all situations.
Bribery & Corruption
CanaQuest Medical Corp has a zero tolerance towards bribery and corruption, and is committed to acting professionally, ethically, and fairly in its business dealings and relationships. This means that we will neither accept nor offer a bribe under any circumstance. Further, we will not partner with any entity that engages in bribery. Companies with which we do business may be confident that CanaQuest Medical Corp is committed to fairness in the market.
Mission
To advance cannabinoid & botanical based medicine to the forefront by deploying best practice science, clinical trials, and emerging technologies.
Problem Mental Disorders On the Rise
- Global cost mental disorders will cost the global economy 16 trillion by 2030¹
- Mental health ailments 1 in 5 North Americans has some type of mental health condition 2,3
- Limited science backed cannabinoid natural plant solutions
- Physicians have a difficult time prescribing cannabinoid precise doses
- Neurological treatment limitations cannabidiol ( by itself is not effective for mental health
- Only one CBD pharmaceutical drug on the market, Epidiolex approved by the US FDA
- Psychiatric Times, November 2018
- Open Minds, May 13 2020
- Mental Health Commission of Canada
Solution Game Changing Formulations
CQ - 001 cannabidiol CBD) IP formula
Drug candidate
- Molecules bond and synergistically attach to PPAR receptors allowing formula to cross the blood brain barrier (BBB);
- Reaches inside central nervous system (the brain) with amplified effects and efficacy
- CBD by itself did not do this in the pre clinical trials
Pre clinical trial results published in peer reviewed European Journal of Neuroscience Oct 2020
CQ-002 cannabinoid ( IP formula + IP formula)
Drug candidate
- A safer alternative to all other THC products
- Pre clinical trials demonstrated reversal of depression like and schizophrenia related symptoms, and
- Blockage of memory impairment, hyperactive activity, and gene vulnerability
Pre clinical trial results published in peer reviewed Journal of Neuroscience Dec 2020 International Journal of Molecular Sciences July 2021
Note: International Patents filed
Pre-clinical trials completed – Western Univ...
- Pre-clinical trials completed – Western University
- Pre-approved and Pending Clinical Trials
- University of Montreal (Phase II)………pre-approved and funded
- McMaster University (Phase II)…………pre-approved and funded
- Ontario Brain Institute (Phase II/III)….clinical study funded & a pending clinical trial
- Regulatory pathways mapped out to obtain Rx Drug Identification Numbers (DINs) in the USA and Canada for Epilepsy rare neurological conditions, projected ∼ 3 years
Note (1): Formulation bases for drug candidates to conduct clinical trials to treat:
- Anxiety & Depression
- PTSD, Schizophrenia
- Pain Management
- Addiction
- Other neurological conditions
The Scientific Difference CBD vs. CQ-001
Pure Cannabidiol
Scientifically developed proprietary formula
CBD……
- Does not effectively cross the blood-brain barrier “BBB“
- Thus, CBD alone is marginally effective for treating mental ailments.
- Can cause negative side effects (especially toxicity of the liver) with high doses.
CQ-001 – pre-clinical trials demonstrated…...
- New Pathway Discovery: Molecules bond and synergistically attach to PPAR receptors allowing CQ-001 to enter the brain, with amplified effects and efficacy.
- Addresses neurological conditions such as epilepsy, including anxiety, depression, PTSD, schizophrenia and addiction.
- Requires minimum doses of CBD, yielding increased efficacy since CQ-001 effectively crosses the BBB.
* Data derived from scientific research and pre-clinical trials by Dr. Steven Laviolette, Neuroscientist, Western University.
Pharmaceutical Comparable - Unique Formulation
CQ 001
Double acting formula on the center nervous system (the brain) and endocannabinoid system
- Active ingredients: CBD + IP formula
- Molecules bond & synergistically cross the blood-brain barrier
- Multible X more efficacy
- Lower dose of CBD required
- Sublingual delivery (spray, under the tongue, buccal) - bypassing digestive system, eliminating liver toxicity
- 80% to 90% of formula enters bloodstream
- Onset within minutes
- Proprietary formulation, CQ-001 - Pricing TBD
Epidiolex
Acts on the endocannabinoid system, requiring high dosage to reach desired results at the brain level
Formula: 99% CBD – sesame as carrier oil (non-active)
- Oral delivery - can lead to liver toxicity
- Only 10% of the formula enters the blood stream
- Effect in hours
Pure CBD, Epidiolex® Rx ∼ US$1,500/100ml
The Scientific Difference THC vs CQ 002
Pure Cannabinoid Scientifically developed proprietary formula
THC can cause……
- Memory impairment & possible long-term cognitive side effects
- Depression-like and schizophrenia-related symptoms
- Anxiety and hyperactive activity
- Schizophrenia due to gene vulnerability
CQ-002 (a safer alternative to THC) – pre-clinical trials demonstrated…...
- Blockage of memory impairment
- Reduced depression-like and schizophrenia related symptoms, such as paranoia
- Blockage of hyperactive activity and anxiety
- Blockage of gene vulnerability related cognitive issues*
* Data derived from scientific research and pre-clinical trials by Dr. Steven Laviolette, Neuroscientist, Western University.
Mental Health Costs
$16 Trillion
Mental Illness Will Cost the World $16 USD Trillion by 2030¹
$225 Billion
Mental Health Costs in the US reached $225 USD Billion in 2019 - 5.5% of all health spending2
$50 Billion
Mental Illness in Canada is at least $50 Billion per year and growing substantially³
51.5 Million
20.6% (1 in 5) of U.S. adults experienced mental illness in 2019 (51.5 million people)4.
- Psychiatric Times, November 2018
- Open Minds, May 13, 2020
- Mental Health Commission of Canada
- National Alliance on Mental Illness (NAMI)
Target Market
- Near Term: USA, Canada, UAE
- Intermediate: Mexico
- Long Term: Europe, UK, Far East
- South America, Africa.
Target Audience
Drivers:
- Medical and Wellness Purposes
- Favorable Government Regulations
- Growing Awareness and Adoption for various Health Conditions
Executive Team, Board of Directors
Richard Rusiniak, Mechanical Engineer, CEO - Director
Over 35 years of management, design and process experience;
Co-founder and former President, CFO, and CTO of Cymat Corp (TSX: CYM) with a market valuation of $200 million;
Paul Ramsay, BBA, President - Chairman
Over 30 years of business development and management experience;
Co-founder and former CEO and VP Business Development of Cymat Corp, (TSX: CYM) with a market valuation of $200 million;
Ross Eastley, CA, CFO - Director
Over 35 years of accounting and CFO experience in both private and public sector organizations;
Former CEO for the Canadian Society of Immigration Consultants (CSIC);
Cameron McDonald, BA, BSc, MBA - Independent Director
Venture capital executive and entrepreneur with over 25 years of corporate finance and business development experience;
Currently the CEO of Ocean Trout Canada Inc., a leading Canadian aquaculture company;
Darrell Stern, MA Communications, Chief Marketing Officer (CMO) - Video Inbound and Content Marketing, SEO
Mr. Stern has grown the value proposition of several B2B and B2C companies worldwide.
Scientific Partners & Regulatory Advisors
Dr. Steven Laviolette, B.Sc., Ph.D., a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University,
Addiction Research Group Dept. of Anatomy & Cell Biology, Dept. of Psychiatry R & D Program - 14 scientists
For a short video on the research.
Dr. David W.L. Ma, Ph.D. Medical Sciences, Professor, Department of Human Health and Nutritional Sciences, University of Guelph
R & D Program - 5 scientists
Previously, had faculty position in the Department of Nutritional Sciences at the University of Toronto
Dr. Adronie Verbrugghe, Ph.D., Associate Professor, Veterinary College, University of Guelph
Graduated as a companion animal veterinarian (DVM) from Ghent University, Belgium in 2005, completed her PhD focusing on nutritional modulation of carbohydrate metabolism in cats in 2009 and 2 additional years as a postdoctoral fellow
Dr. Tom Ng, B.S., Ph.D., COO, BioPharma Global, Regulatory Consultants - 7 Leadership Team Members
Dr. Ng’s academic background includes a B.S. in Biochemistry from the University of Maryland and a Ph.D. in Molecular Biology from Johns Hopkins University. He is also an Executive Board Member and President Emeritus of the CMNS Alumni Association Chapter at the University of Maryland
CanaQuest Highlights
- Leader - in cannabinoid-based drug development for treating mental health neurological conditions
- Clinical trial stage - strong science, pre-clinical trial results and peer-reviewed reputable publications for drug candidates, CQ-001 & CQ-002
- Game changers - CQ-001 synergistically attaches to PPAR receptor allowing CBD to cross the blood-brain barrier (BBB) to interact with the central nervous system (the brain) for amplified effects & CQ-002 - a safer alternative to all other THC products
- Clinical trials - Drug Candidates CQ-001 & CQ-002, University of Montreal Phase II, McMaster University Phase II, and Ontario Brain Institute Phase II/III
- Regulatory pathways - mapped out to obtain Rx Drug approvals for Epilepsy rare diseases, ∼ 3 years
- Exit via acquisition - GW Pharma acquired by Jazz Pharma for $7.2 B, 2.5 years after launching Epidiolex®
- Near term revenue - Nutraceutical product rollout, Mentanine®.
Roadmap Post Funding
Q - 1
- Post funding
- Initiate listing on the Canadian Securities Exchange (CSE)
- Ecommerce store launch & product rollout
- Engage BioPharma Global,
- Establish regulatory program with US FDA and Health Canada,
- Initiate University of Guelph R & D Program.
Q -2
- Applications for Clinical Trials,
- Initiate Clinical Trial at McMaster on Anxiety,
- Further pre clinical trial research @ Western
- Achieve listing on the CSE with an up listing to US OTCQX
- Distribution expansion
Q - 3
- Launch Mentabinol in Canada
- Initial Cannabis Use Disorder Clinical Trial (CUD)
- Undertake a capital raise
Q - 4
- Initiate Clinical Trial for epilepsy in Canada,
- Increase distribution network for US & Canada for Mentanine
- Export to Europe
- Set up production outside Canada & USA
